N-myc downstream-regulated gene 2 protein (NDRG2)

N-myc downstream-regulated gene 2 protein (NDRG2) is a cytoplasmic protein encoded by the NDRG2 gene in humans, classified as a nonenzymatic member of the alpha/beta hydrolase superfamily. It is structurally similar to enzymes but lacks catalytic activity. NDRG2 functions primarily as a tumor suppressor, inhibiting cell proliferation, metastasis, and promoting apoptosis through modulation of transcriptional regulatory pathways (such as Wnt/β-catenin, NF-κB, and PI3K/AKT), stress responses, and epigenetic mechanisms. Its expression is associated with cancer prognosis and therapeutic sensitivity, and genomic loss or promoter silencing is linked to aggressive tumors. NDRG2 is being explored as a therapeutic target, biomarker for patient selection, and mediator of cellular response to anticancer drugs, particularly through p53-mediated and DAPK1-mediated apoptosis. NDRG2-related pathways also intersect with neurodegenerative diseases and cell differentiation processes. No direct drugs targeting NDRG2 are clinically available, but regulatory and apoptotic pathways connected to it are subject to targeted therapies in oncology and related fields[1][2][3][4][5][6].

Other names

NDRG family member 2NDRG2KIAA1248SYLDN-myc downstream-regulated gene 2 proteinProtein Syld709613NDR1-related protein NDR2cytoplasmic protein Ndr1

Increase in apoptosis: NDRG2 expression sensitizes cells to apoptotic cell death, especially in response to cancer drugs. Inhibition of cell proliferation/metastasis: Via suppression of Wnt/β-catenin, c-Jun/cyclin D, and NF-κB signaling. Epigenetic regulation: Drugs or strategies that increase NDRG2 expression via promoter demethylation or p53 activation are hypothesized to improve cancer outcomes.